# US 2010/0167421 A1 · Methods for identification and prediction of multiple sclerosis disease and therapy response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167421 A1
- Document ID: US20100167421A1
- Status: Published application
- Kind: A1
- Application number: 12/563,995
- Filed: 2009-09-21
- Published: 2010-07-01
- Earliest claimed: 2008-09-19
- Assignees: University of Utah Research Foundation; Lineagen, Inc.
- Inventors: John W. Rose; Mark F. Leppert
- Web page: https://patentgrep.com/patent/US20100167421A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/172: Haplotypes
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions for diagnosing multiple sclerosis (“MS”) in an individual or the predisposition or risk of MS, and for the prediction of the response to treatment of MS in an individual. More particularly, methods and compounds for the use of clinical, neuroradiological, genetic, biological and/or immunological markers as prognostic indicators, diagnostic markers, or predictors of response to MS therapy.

## Claims

### Claim 1

A method of determining the susceptibility to multiple sclerosis (MS) in an individual, the method comprising:
assaying for the presence in the individual of at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.: 1-171;
wherein the presence in the individual of the at least one allele of a SNP associated with MS is indicative that the individual is susceptible to MS.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
assaying for the presence or absence in the individual of at least one biomarker associated with MS, wherein the presence in the individual of the at least one allele of a SNP associated with MS, and the presence in the individual of the at least one biomarker associated with MS, is indicative that the individual is susceptible to MS.

### Claim 3 (depends on 2)

The method of claim 2, wherein the at least one biomarker is selected from the group consisting of at least one anti-thyroid antibody, at least one cytokine, and at least one immunomodulating agent, or combinations thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein the at least one biomarker is at least one of TNF-α, IL-1β, (3, IL-6, IL-8, IL-4, IL-5, IL-10, IL-13, IFN-γ, IL-2, IL-12, CD-40L and IL-2r.

### Claim 5 (depends on 4)

The method of claim 4, wherein assaying for the presence of the at least one biomarker in the individual comprises assaying the blood plasma level of at least one of TNF-α, IL-1β, IL-6, IL-8, IL-4, IL-5, IL-10, IL-13, IFN-γ, IL-2, IL-12, CD-40L and IL-2r, at a level approximately greater than the mean blood plasma level of the at least one biomarker in a normal healthy control population.

### Claim 6 (depends on 4)

The method of claim 4, wherein the at least one biomarker is selected from the group consisting of IL-1β, IL-2, IL-6, TNF-α, and IL-4.

### Claim 7 (depends on 2)

The method of claim 2, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of the nucleotide sequences identified by SEQ ID NO.: 147, SEQ ID NO.: 148, SEQ ID NO.: 149, and SEQ ID NO.: 150, or combinations thereof, and wherein the at least one biomarker is selected from the group consisting of IL-1β, IL-2, IL-6, TNF-α.

### Claim 8 (depends on 2)

The method of claim 2, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of the nucleotide sequences identified by SEQ ID NO.: 155 and SEQ ID NO.: 156, or combinations thereof, and wherein the at least one biomarker is IL-4.

### Claim 9 (depends on 7)

The method of claim 7, wherein the at least one biomarker is IL-1β and is detected at a blood plasma level approximately greater than the mean blood plasma level of IL-1β in a normal healthy control population.

### Claim 10 (depends on 9)

The method of claim 9, wherein IL-1β is detected at a blood plasma level of approximately 35 pg/mL.

### Claim 11 (depends on 7)

The method of claim 7, wherein the at least one biomarker is IL-2 and is detected at a blood plasma level ranging from approximately greater than the mean blood plasma level of IL-2 in a normal healthy control population.

### Claim 12 (depends on 11)

The method of claim 11, wherein IL-2 is detected at a blood plasma level of approximately 7 pg/mL.

### Claim 13 (depends on 7)

The method of claim 7, wherein the at least one biomarker is IL-6 and is detected at a blood plasma level ranging from approximately greater than the mean blood plasma level of IL-6 in a normal healthy control population.

### Claim 14 (depends on 13)

The method of claim 13, wherein IL-6 is detected at a blood plasma level of approximately 12 pg/mL.

### Claim 15 (depends on 7)

The method of claim 7, wherein the at least one biomarker is TNF-α and is detected at a blood plasma level ranging from approximately greater than the mean blood plasma level of TNF-α in a normal healthy control population.

### Claim 16 (depends on 15)

The method of claim 15, wherein TNF-α is detected at a blood plasma level of approximately 2 pg/mL.

### Claim 17 (depends on 8)

The method of claim 8, wherein IL-4 is detected at a blood plasma level ranging from approximately greater than the mean blood plasma level of TNF-α in a normal healthy control population.

### Claim 18 (depends on 17)

The method of claim 17, wherein IL-4 is detected at a blood plasma level of approximately 3 pg/mL.

### Claim 19

A method of determining the MS disease state of an individual, the method comprising:
assaying the individual for at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.: 1-171;
detecting in the individual the at least one allele of a SNP associated with MS;
wherein detecting in the individual the at least one allele of a SNP associated with MS is indicative of the MS disease state of the individual, wherein the MS disease state is selected from the group consisting of Relapsing-Remitting (RR), Primary-Progressive (PP), Secondary-Progressive (SP), and Progressive-Relapsing (PR).

### Claim 20 (depends on 19)

The method of claim 19, further comprising:
assaying the presence or absence of at least one biomarker associated with MS in the individual, wherein detecting in the individual the at least one allele of a SNP associated with MS, and detecting the presence of the at least one biomarker in the individual, is indicative of the MS disease state of the individual.

### Claim 21 (depends on 3)

The method of claim 3, wherein the anti-thyroid antibody is at least one of anti-thyrpoetin and anti-thyroglobulin.

### Claim 22

A method of predicting the response of an individual to at least one MS therapy, the method comprising:
detecting in the individual at least one anti-thyroid antibody, wherein the presence of the at least one anti-thyroid antibody is indicative of the response to the at least one MS therapy.

### Claim 23 (depends on 22)

The method of claim 22, wherein the anti-thyroid antibody is at least one of anti-thyrpoetin and anti-thyroglobulin.

### Claim 24 (depends on 23)

The method of claim 23, wherein anti-thyroid antibody is anti-thyropoetin and it is detected at a level of 100 IU or greater.

### Claim 25 (depends on 23)

The method of claim 23, wherein the anti-thyroid antibody is anti-thyroglobulin and it is detected at a level of 50 IU or greater.

### Claim 26 (depends on 22)

The method of claim 22, wherein detecting the presence or absence of the at least one anti-thyroid antibody is indicative of an improved ambulatory outcome for the individual.

### Claim 27 (depends on 22)

The method of claim 22, wherein predicting the response of the individual to at least one MS therapy further comprises assigning the individual to a sub-population of MS patients.

### Claim 28 (depends on 22)

The method of claim 22, wherein the at least one MS therapy is at least one immunotherapy.

### Claim 29

An in vitro diagnostic product comprising:
at least one laboratory test for assaying for the presence in the individual of at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.: 1-171; and
at least one laboratory test for assaying for the presence or absence in the individual of at least one biomarker associated with MS.

### Claim 30

An in vitro diagnostic product for indicating the susceptibility of MS in an individual, the product comprising:
at least one laboratory test for assaying for the presence in the individual of at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.: 1-171;
at least one laboratory test for assaying for the presence or absence in the individual of at least one biomarker associated with MS;
wherein the presence in the individual of the at least one allele of a SNP associated with MS, and the presence in the individual of the at least one biomarker associated with MS, is indicative that the individual is susceptible to MS.
